Latest Industry Insights
Industry Insight
Investigating the Medical Potential of Cannabis-derived Products
We recently had the pleasure of speaking with William Levine, D.D.S., CannRx Founder and Chief Scientific Officer. Levine discusses CannRx’s mission to develop transformative, scientifically based, proprietary cannabis technologies, highlights some of the medical applications of cannabis-derived products, and explains why it is so important to analyze the various active compounds in cannabis.
Industry Insight
Harnessing the Immune System for Early Cancer Detection
With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.
Industry Insight
Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders
Technology Networks recently had the pleasure of speaking with Bruce Steel, CEO Equillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.
Industry Insight
Different by Design: The Impact of Drug Delivery Device Design on the Future of the Biosimilars Market
The pharmaceutical market is in a period of transition as the introduction of new biosimilars increases. Here, George I'ons, Owen Mumford Pharmaceutical Services, explores a lesser known but albeit important factor influencing the success of this transitional period is delivery device design of such drugs.
Industry Insight
Will the Potential of Proteomics Be Realized in 2020?
Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.
Industry Insight
Studying Molecular Systems With Digital High-throughput SPR
Speaking to Technology Networks, Ryan Denomme highlights the key challenges faced when using “traditional” surface plasmon resonance (SPR), how SPR is being used to aid drug discoveries, and explains the benefits of designing an SPR instrument that integrates digital microfluidics, artificial intelligence, and nanotechnology.
Industry Insight
The Power of Positrons
Over the last five to ten years, multi-modal imaging has become established as a significant component of a preclinical researcher’s analytical toolbox. Here, we highlight perhaps the most used and certainly the most sensitive and quantitative of these imaging modalities, the combination of positron emission tomography (PET) with X-ray computed tomography (CT), or PET/CT.
Industry Insight
Driving Medical Innovation To Improve the Lives of Patients
Technology Networks recently spoke with LifeArc’s CEO Melanie Lee, PhD, CBE. Melanie elaborates on LifeArc's mission, discusses the importance of bridging the gap between "bench" and "bedside", and highlights how genomics can help drive earlier intervention.
Industry Insight
Drug Candidate for Lung Cancer Receives FDA Fast Track Designation
Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex, a lead drug candidate that treats non-small cell lung cancer, and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.
Industry Insight
Leveraging AI To Find the “Right” Clinical Trial
Less than 5% of adult cancer patients enroll in clinical trials even though it is estimated that a large percentage (70% of Americans) are very willing to take part in a clinical study. So, why is there such a large discrepancy in the number of actual participants versus those willing to, but not actually participating?
Advertisement